NewAmsterdam CEO Michael Davidson Buys 10,000 Shares

What Happened
Michael H. Davidson, CEO of NewAmsterdam Pharma Co. N.V. (NAMS), purchased 10,000 ordinary shares in an open‑market transaction on 2026-09-14 at $22.65 per share, for a total cost of $226,500. This was a buy (purchase) transaction rather than a sale or option exercise.

Key Details

• Transaction date and price: 2026-09-14 — 10,000 shares at $22.65 each (total $226,500).
• Transaction type: Open‑market purchase (code P).
• Filing date: Form 4 filed 2026-09-15 for the 2026-09-14 transaction (filed the next day; appears timely).
• Shares owned after transaction: Not specified in the provided filing excerpts.
• Notable footnotes from the filing:
  • F1: Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
  • F2: Reflects prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the reporting person; those were held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person.
  • F3: Some ordinary shares are held by the "Michael H. Davidson 2026 Grantor Retained Annuity Trust (GRAT)"; Davidson is the sole annuitant and trustee of the GRAT.

Context
This was a straightforward open‑market purchase by the CEO (not an option exercise, gift, or tax withholding). Purchases by insiders can be of interest to investors as one data point about management’s view, but they do not by themselves explain motive or future company performance.